TASP1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL10039101	1.00	2/20
SCHEMBL10039102	1.00	2/20
SCHEMBL18499095	0.63	2/20
SCHEMBL2900024	0.52	2/20
SCHEMBL7128280	0.46	2/20
SCHEMBL345316	1.00	1/20
SCHEMBL10068891	1.00	1/20
SCHEMBL10069051	1.00	1/20
SCHEMBL10069054	1.00	1/20
SCHEMBL10069116	1.00	1/20
SCHEMBL10069516	1.00	1/20
SCHEMBL10069515	0.85	1/20
SCHEMBL1898696	0.81	1/20
SCHEMBL10069115	0.73	1/20
SCHEMBL1899805	0.71	1/20
SCHEMBL22999953	0.68	1/20
SCHEMBL1898992	0.68	1/20
SCHEMBL1900846	0.67	1/20
SCHEMBL1899142	0.65	1/20
SCHEMBL1903539	0.65	1/20

Clinical trials — most relevant to TASP1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Trial of CM-AT in Children With Autism With All Levels of FCT (The Blum Study)	PHASE3	COMPLETED
Safety and Impact of Dasatinib on Viral Persistence and Inflammation in People With HIV Under Antiretroviral Treatment	PHASE2	COMPLETED
Sirolimus Treatment in Patients With Autosomal Dominant Polycystic Kidney Disease: Renal Efficacy and Safety	PHASE2	COMPLETED
A Phase II Study of TX Regimen as First-line Treatment for Asian Elderly Patients With Advanced Adenocarcinoma of Lung	PHASE2	COMPLETED
Effects of Vitamin B3 in Patients With Ataxia Telangiectasia	PHASE2	COMPLETED
Reverse Transcriptase Inhibitors in AGS	PHASE2	COMPLETED
Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid Tumors	PHASE1	COMPLETED
D-aspartate and Therapeutic Exercise	EARLY_PHASE1	UNKNOWN
Vegetables Intake and Polymorphism TAS2R38 Gene by Healthy Adults	nan	COMPLETED
TAS1R1, TAS1R3, TLR2, TLR4, CA6 Gene Polymorphism on Dental Caries	nan	COMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer	nan	UNKNOWN
Polycystic Ovary Syndrome in Type 1 Diabetes	nan	NOT_YET_RECRUITING
Integrated Proteomic HPLC-ESI-MS Analysis of Salivary Peptides of Preterm Newborns: a Pilot Study	nan	COMPLETED
Molecular Genetic Epidemiology of Endocardial Cushion Defects - SCOR in Pediatric Cardiovascular Disease	nan	COMPLETED
A National Retrospective Population Based Cohort Study of the Natural History of Ataxia Telangiectasia	nan	UNKNOWN
Whole Body MRI for Cancer Surveillance in A-T	nan	COMPLETED
Study of Taste Deficits	nan	COMPLETED
Biomarker Research in Inherited Movement Disorders	nan	RECRUITING
Role of Sorcin and Annexin A3 in Breast Cancer Patients	nan	UNKNOWN
Genome Environment Microbiome and Metabolome in Autism Study	nan	COMPLETED
Genetic Analyses of Nonsyndromic and Syndromic Deafness in Pakistan	nan	ENROLLING_BY_INVITATION
Apoptosis Markers in Aggressive Periodontitis	nan	COMPLETED
Marker of Brain Insulin Resistance in AD Prognosis	nan	NOT_YET_RECRUITING
Susceptibility to Infections in Ataxia Telangiectasia	nan	COMPLETED
Aswan Heart Centre - Egyptian Healthy Volunteers	nan	RECRUITING
Study of Genotype and Phenotype Characterization in Duchenne Muscular Dystrophy With Small Mutations	nan	UNKNOWN
MOLECULAR REGULATION OF MUSCLE GLUCOSE METABOLISM (AIMS 2A, 2B, 3)	nan	UNKNOWN
JAK-STAT Signalling Pathway in Familial Myeloproliferative Disorders	nan	COMPLETED
Speech and Short-term Memory Functions in Dyslexia: a Combined MEG and EEG Study	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a TASP1 binder may also engage these)

Protein	Name	Similarity
Q8R1G1	—	1.000	Q8R1G1 →
Q3ZBL5	—	0.949	Q3ZBL5 →
Q4R4U1	—	0.946	Q4R4U1 →
Q9NVE7	—	0.946	Q9NVE7 →
Q5R5F8	—	0.946	Q5R5F8 →
Q923S8	—	0.943	Q923S8 →
A4FUF0	—	0.941	A4FUF0 →
METTL16	RNA N(6)-adenosine-methyltransferase METTL16	0.941	landscape →
Q5R7T2	—	0.941	Q5R7T2 →
O15315	—	0.941	O15315 →
Q5RKH0	—	0.940	Q5RKH0 →
Q7Z6V5	—	0.940	Q7Z6V5 →
Q7Z624	—	0.939	Q7Z624 →
Q922P9	—	0.939	Q922P9 →
Q9CQG2	—	0.938	Q9CQG2 →
Q6AXQ0	—	0.937	Q6AXQ0 →
Q5ZIA0	—	0.937	Q5ZIA0 →
Q6P6J0	—	0.937	Q6P6J0 →
Q5ZLS7	—	0.937	Q5ZLS7 →
Q49A26	—	0.937	Q49A26 →
Q91YD4	—	0.936	Q91YD4 →
Q8CIW5	—	0.936	Q8CIW5 →
Q6DC64	—	0.936	Q6DC64 →
Q9R1T2	—	0.936	Q9R1T2 →
Q96RR1	—	0.935	Q96RR1 →
Q9Y3E5	—	0.934	Q9Y3E5 →
RO60	RNA-binding protein RO60	0.934	landscape →
Q5RKN4	—	0.933	Q5RKN4 →
Q6P4H8	—	0.933	Q6P4H8 →
Q8NHH1	—	0.932	Q8NHH1 →